Latest Conference Articles

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

Adding the CD38-directed monoclonal antibody isatuximab in combination with pomalidomide and dexamethasone improved progression-free survival in both standard-risk patients with relapsed/refractory multiple myeloma and those with high-risk cytogenetics.

Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.

Pieter Sonneveld, MD, PhD, discusses the significance of the subgroup analysis of the phase III CASSIOPEIA trial evaluating the regimen of daratumumab, bortezomib, thalidomide, and dexamethasone in patients with high-risk multiple myeloma.

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Targeted therapies for non­–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.